BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25655603)

  • 21. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.
    Trojani A; Di Camillo B; Bossi LE; Leuzzi L; Greco A; Tedeschi A; Frustaci AM; Deodato M; Zamprogna G; Beghini A; Cairoli R
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33921415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
    Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
    Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry.
    Ocio EM; del Carpio D; Caballero Á; Alonso J; Paiva B; Pesoa R; Villaescusa T; López-Anglada L; Vidriales B; García-Sanz R
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):93-5. PubMed ID: 21454201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
    Schmidt K; Sack U; Graf R; Winkler W; Popp O; Mertins P; Sommermann T; Kocks C; Rajewsky K
    Front Immunol; 2020; 11():602868. PubMed ID: 33343574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia.
    Atrash S; Zhang Q; Papanikolaou X; Stein C; Abdallah AO; Barlogie B
    J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
    Schop RF; Van Wier SA; Xu R; Ghobrial I; Ahmann GJ; Greipp PR; Kyle RA; Dispenzieri A; Lacy MQ; Rajkumar SV; Gertz MA; Fonseca R
    Cancer Genet Cytogenet; 2006 Sep; 169(2):150-3. PubMed ID: 16938573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Trojani A; Greco A; Tedeschi A; Lodola M; Di Camillo B; Ricci F; Turrini M; Varettoni M; Rattotti S; Morra E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):208-10. PubMed ID: 23477935
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Yu X; Li W; Deng Q; Li L; Hsi ED; Young KH; Zhang M; Li Y
    Cancer Res; 2018 May; 78(10):2457-2462. PubMed ID: 29703722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia.
    Tahri S; Mouhieddine TH; Redd R; Lampe L; Nilsson KI; El-Khoury H; Su NK; Nassar AH; Adib E; Bindra G; Abou Alaiwi S; Trippa L; Steensma DP; Castillo JJ; Treon SP; Ghobrial IM; Sperling AS
    Blood Adv; 2022 Apr; 6(7):2230-2235. PubMed ID: 34847227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition.
    McMaster ML; Caporaso N
    Br J Haematol; 2007 Dec; 139(5):663-71. PubMed ID: 18021080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
    Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
    Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Nakamura A; Ohwada C; Takeuchi M; Takeda Y; Tsukamoto S; Mimura N; Nagisa OH; Sugita Y; Tanaka H; Wakita H; Aotsuka N; Matsue K; Yokote K; Ohara O; Nakaseko C; Sakaida E
    PLoS One; 2019; 14(9):e0221941. PubMed ID: 31483817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors predicting transformation of asymptomatic IgM monoclonal gammopathy.
    Greco A; Tedeschi A; Varettoni M; Nichelatti M; Paris L; Ricci F; Vismara E; Morra E
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):77-9. PubMed ID: 21454196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.
    Jiménez C; Prieto-Conde MI; García-Álvarez M; Alcoceba M; Escalante F; Chillón MDC; García de Coca A; Balanzategui A; Cantalapiedra A; Aguilar C; Corral R; González-López T; Marín LA; Bárez A; Puig N; García-Mateo A; Gutiérrez NC; Sarasquete ME; González M; García-Sanz R
    Ann Hematol; 2018 Mar; 97(3):475-484. PubMed ID: 29353304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
    Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
    Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
    Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery.
    Kriangkum J; Taylor BJ; Strachan E; Mant MJ; Reiman T; Belch AR; Pilarski LM
    Blood; 2006 Apr; 107(7):2920-7. PubMed ID: 16317092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.
    Grass S; Preuss KD; Wikowicz A; Terpos E; Ziepert M; Nikolaus D; Yang Y; Fadle N; Regitz E; Dimopoulos MA; Treon SP; Hunter ZR; Pfreundschuh M
    Blood; 2011 Mar; 117(10):2918-23. PubMed ID: 21220746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
    Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.